Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Personalized colon cancer care starts with genomic testing

Minimal surgery. Partial colectomy. Radiation. Chemotherapy. Some, or all. When it comes to colon cancer, there’s a whole arsenal of treatment options. But which one is right for you? Which treatment regimen will fight hardest against your particular colon cancer tumor?

With the help of insights from the advanced genomics of the Oncotype DX Colon Recurrence Score® test, you and your doctor can make informed treatment decisions based on the characteristics of your unique tumor and the risk of it recurring.

For patients with stage II or stage IIIA/B colon cancer, learn about the only genomic test proven to predict how likely your cancer is to return. Plus, get an understanding of the testing process, and what you can expect from the results.

$0
financial responsibility for Colon Recurrence Score® test when Medicare fee-for-service (FFS) coverage criteria are met

Medicare Advantage, which is provided by commercial insurance companies, may have different financial responsibility compared to Medicare FFS.